New drug combo aims to tame Graft-Versus-Host disease
NCT ID NCT07185633
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a new drug called Gecacitinib combined with steroids as the first treatment for moderate to severe graft-versus-host disease (aGVHD) that can occur after a stem cell transplant. The trial will enroll 25 adults who have recently received a transplant and have not yet been treated for aGVHD for more than 2 days. Participants will take the drug combination for at least 28 days, and if their condition improves, they may continue treatment for up to 24 weeks. The main goal is to see how many patients respond to the treatment by day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGVHD are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.